Assessment of Primary Malignancy Risk after Initiation of Biologic Therapy in Patients with Psoriasis
Limited evidence exists regarding the long-term oncologic safety of biologic therapies, particularly IL-17 inhibitors and IL-23 inhibitors, in the management of psoriasis. This propensity score–matched retrospective cohort study assessed the risk of developing a primary malignancy within 10 years af...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-11-01
|
| Series: | JID Innovations |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667026725000530 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|